Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas

NCT06465199 is registered in ClinicalTrials.gov with Milton S. Hershey Medical Center as lead sponsor.

NCT NCT06465199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study Using Eflornithine (DFMO) and AMXT 1501 for Relapsed and Refractory Neuroblastoma, CNS Tumors, and Sarcomas
Lead sponsor
Milton S. Hershey Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 13, 2026
Completion date
May 31, 2035
Enrollment
265 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

atypical teratoid/rhabdoid tumor, diffuse intrinsic pontine glioma, dipg brain tumor, embryonal tumor with multilayered rosettes, ewing sarcoma, neuroblastoma, osteosarcoma